ArticleCancer biomarkers : section A of Disease markers2017
Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis.
Article in Cancer biomarkers : section A of Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- In silico design of the multi-epitope vaccine for lung adenocarcinoma based on hub gene-derived neoantigens.BMC cancer · 2026Article
- mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors.Cancer research communications · 2024Article
- An AI Approach to Identifying Novel Therapeutics for Rheumatoid Arthritis.Journal of personalized medicine · 2023Review
- Microfluidic single-cell migration chip reveals insights into the impact of extracellular matrices on cell movement.Lab on a chip · 2023Article
- Robust Identification of Differential Gene Expression Patterns from Multiple Transcriptomics Datasets for Early Diagnosis, Prognosis, and Therapies for Breast Cancer.Medicina (Kaunas, Lithuania) · 2023Article
- Identification of genomic biomarkers and their pathway crosstalks for deciphering mechanistic links in glioblastoma.IET systems biology · 2023Article
- A Ribosome-Related Prognostic Signature of Breast Cancer Subtypes Based on Changes in Breast Cancer Patients' Immunological Activity.Medicina (Kaunas, Lithuania) · 2023Article
- Proteomic profiling of urinary extracellular vesicles differentiates breast cancer patients from healthy women.PloS one · 2023Article
- Integrative bioinformatics and RNA sequencing based methodology results in the exploration of breast invasive carcinoma biomarkers.American journal of translational research · 2023Article
- An integrative approach toward identification and analysis of therapeutic targets involved in HPV pathogenesis with a focus on carcinomas.Cancer biomarkers : section A of Disease markers · 2023Article
- Krüppel-like factor 7 influences translation and pathways involved in ribosomal biogenesis in breast cancer.Breast cancer research : BCR · 2022Article
- Thorough statistical analyses of breast cancer co-methylation patterns.BMC genomic data · 2022Article
- RPS9 promotes the progression of NSCLC via activation Stat3 and Erk signaling pathways.Journal of Cancer · 2022Article
- A network pharmacology-based investigation on the bioactive ingredients and molecular mechanisms of Gelsemium elegans Benth against colorectal cancer.BMC complementary medicine and therapies · 2021Article
- A Novel 8-Gene Prognostic Signature for Survival Prediction of Uveal Melanoma.Analytical cellular pathology (Amsterdam) · 2021Article
- The Advantages of Connectivity Map Applied in Traditional Chinese Medicine.Frontiers in pharmacology · 2021Review
- Quantitative Proteomic Profiling Identifies a Potential Novel Chaperone Marker in Resistant Breast Cancer.Frontiers in oncology · 2021Article
- Article
- Article
- Prognostic roles of the expression of sphingosine-1-phosphate metabolism enzymes in non-small cell lung cancer.Translational lung cancer research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is the second most common cause of death from cancer in women in the United States. As the molecular mechanism of BC has not yet been completely discovered, identification of hub genes and pathways of this disease is of importance for revealing molecular mechanism of breast cancer initiation and progression.
objectiveThis study aimed to identify potential biomarkers and survival analysis of hub genes for BC treatment.
methodsThe differentially expressed genes (DEGs) between breast cancer and normal cells were screened using microarray data obtained from the Gene Expression Omnibus (GEO) database. Gene ontology (GO) and KEGG pathway enrichment analyses were performed for DEGs using DAVID database, the protein-protein interaction (PPI) network was constructed using the Cytoscape software, and module analysis was performed using MCODE. Then, overall survival (OS) analysis of hub genes was performed by the Kaplan-Meier plotter online tool. Finally, the potential molecular agents were identified with Connectivity Map (cMap) database.
resultsA total of 585 DEGs were obtained, which were significantly enriched in the terms related to positive regulation of cell migration, regulation of cell proliferation and focal adhesion. KEGG pathway analysis showed that the significant pathways included Focal adhesion, Pathways in cancer, ECM-receptor interaction, Ribosome, Transcriptional misregulation in cancer and other signaling pathways about cancer. The PPI network was established with 576 nodes and 1943 edges. A significant module was found from the PPI network, the enriched functions and pathways included ECM-receptor interaction and Focal adhesion.
conclusionsFifteen genes were selected as hub genes because of high degrees, among which, low expression of four genes was associated with worse OS of patients with BC, including RPS9, RPL11, RPS14 and RPL10A. Additionally, the small molecular agent emetine may be a potential drug for BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.